• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1001227

全球精神藥物市場分析（2021-2031）：根據冠狀病毒感染（COVID-19）預測的藥物類別，適應症，最終用戶，主要國家，主要公司的分析預測

Mental Disorder Drugs Market Report 2021-2031: Forecasts by Drug Class, by Indication, by End-user, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios
出版日期: | 出版商: Visiongain Reports Ltd. | 英文 429 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計在預測期內，精神疾病的全球市場將以強勁的複合年增長率增長。諸如抑鬱症，雙相情感障礙，焦慮症和精神分裂症等精神疾病的流行是對精神藥物需求的主要驅動力。新興國家對精神健康的意識增強，採用精神藥物進行治療和維持，以及大型製藥公司在精神健康領域加大研發投入，也是推動市場增長的其他因素。此外，COVID-19大流行對精神藥物市場也產生了重大影響。由於失業，金融危機，健康問題和壓力，COVID-19大流行導致精神疾病的發生率增加。因此，預計在預測期內對精神藥物的需求將會增加。

該報告分析了全球精神疾病藥物市場，並概述了產品，市場的基本結構和最新情況，主要增長和製約因素，市場規模趨勢預測（2021年至2031年），並提供了信息，例如按地區和主要國家/地區劃分的詳細趨勢，主要公司的概況以及來自COVID-19的影響情景。

目錄

第1章報告概述

第2章執行摘要

第3章市場動態

  • 生長因素
    • 先進的精神科藥物的開發
    • 精神疾病的患病率上升
    • 對精神保健的認識提高
  • 抑制因素
    • 新藥開發增加
    • 精神疾病的社會恥辱
    • 嚴格的新藥審批監管指南
  • 市場機會
    • 對支持市場增長的新型精神疾病治療方法的需求不斷增長
    • 老年人口增加
  • 趨勢
    • 市場參與者的合併，協議和收購
    • 預定新藥上市有望促進市場增長
  • SWOT分析
    • 優勢：精神疾病市場最活躍的領域
    • 弱點
    • 市場機會
    • 威脅
  • 波特的五力分析
    • 供應商議價能力：中
    • 買方議價能力：中
    • 競爭對手之間的敵對關係：高
    • 新進入者威脅：中
    • 替代威脅：中
  • PEST分析
    • 影響精神藥物市場的政治因素
    • 影響精神藥物市場的經濟因素
    • 影響精神藥物市場的社會因素
    • 影響精神藥物市場的技術因素

第4章2021-2031年世界市場預測

  • 2021-2031年世界市場預測

第5章COVID-19的影響：全球精神藥物市場

  • "V" 形恢復迅速下降銳利借款迅速恢復
  • "U" 形恢復迅速下降，然後在底部緩慢恢復，在底部緩慢恢復，先是快速恢復，隨後是快速恢復
  • "W" 形恢復-快速下降-快速恢復-病毒復發-另一個快速下降-恢復
  • "L" 形恢復迅速下降，隨後增長減緩

第6章，按藥物類別預測市場規模，2021-2031年

  • 全球SSRI細分市場：收入預測，2021-2031
    • 收入最高的細分市場
    • 恢復預測（V，U，W，L）
  • 全球SNRI細分市場：收入預測，2021年至2031年
    • 越來越多地採用這些藥物來治療精神障礙
    • 恢復預測（V，U，W，L）
  • 全球非典型抗精神病藥物領域：收入預測，2021-2031年
    • 非典型抗精神病藥物市場有望以有利的增長率增長
    • 恢復預測（V，U，W，L）
  • 全球TCA細分市場：收入預測，2021年至2031年
    • 三氯乙酸（TCA）：有助於治療嚴重的抑鬱症
    • 恢復預測（V，U，W，L）
  • 全球SARI細分市場：收入預測，2021年至2031年
    • SARI：主要用於治療MDD
    • 恢復預測（V，U，W，L）
  • 全球苯二氮卓類業務：收入預測，2021-2031年
    • 苯二氮卓類藥物領域：預測期內預期穩定增長
    • 恢復預測（V，U，W，L）
  • 全球MAOI細分市場：收入預測，2021年至2031年
    • MAOI細分市場：預計在預測期內將保持強勁的複合年增長率
    • 恢復預測（V，U，W，L）
  • 世界其他部分：收入預測，2021年至2031年
    • 對先進藥物的需求增加推動了該領域的增長
    • 恢復預測（V，U，W，L）

第7章，按指標預測市場規模，2021年至2031年

  • 全球蕭條部門：收入預測，2021年至2031年
    • 收入最高的細分市場
    • 恢復預測（V，U，W，L）
  • 全球精神分裂症領域：收入預測，2021年至2031年
    • 全世界精神分裂症的患病率不斷上升，推動了細分市場的增長
    • 恢復預測（V，U，W，L）
  • 全球躁鬱症分類：收入預測，2021-2031年
    • 採用通用藥物治療躁鬱症
    • 恢復預測（V，U，W，L）
  • 全球創傷後應激障礙分類：收入預測，2021年至2031年
    • 開發先進的精神藥物的研發成本增加
    • 恢復預測（V，U，W，L）
  • 世界其他部分：收入預測，2021年至2031年
    • 其他精神疾病的患病率增加
    • 恢復預測（V，U，W，L）

第8章2021-2031年按分銷渠道進行的市場預測

  • 2021-2031年醫院藥房細分市場預測
    • 最大的創收部門
    • 恢復方案（V，U，W，L）
  • 2021-2031年零售藥房細分市場預測
    • 市場中增長最快的細分市場
    • 恢復方案（V，U，W，L）
  • 其他細分市場的預測，2021-2031年
    • 醫療基礎設施的發展促進市場增長
    • 恢復方案（V，U，W，L）

第9章，2021-2031年世界市場預測

  • 2021-2031年區域市場預測
  • 恢復方案（V，U，W，L）

第10章，2021-2031年的北美市場

  • 北美是世界市場上最大的收入增長區域
  • 2021-2031年國家市場預測
  • 恢復方案（V，U，W，L）
  • 按藥品類別劃分的市場預測
  • 按指示的市場預測
  • 分銷渠道的市場預測
  • 2021-2031年美國市場預測
    • 藥品批准數量增加
    • 高度發達的醫療基礎設施的存在
    • 復甦情景（V，U，W，L）：美國市場預測，2021年至2031年
  • 2021-2031年加拿大市場預測
    • 預計在北美增長最快
    • 加拿大製造和研發運營的優勢
    • 復甦情景（V，U，W，L）：2021-2031年加拿大市場預測

第11章，2021-2031年的歐洲市場

  • 世界第二大市場
  • 2021-2031年國家市場預測
  • 恢復方案（V，U，W，L）
  • 按藥品類別劃分的市場預測
  • 按指示的市場預測
  • 分銷渠道的市場預測
  • 2021-2031年德國市場預測
    • 預計該地區老年人口的增加將推動該地區市場的增長
    • 歐洲最古老的全民醫療體系之一
    • 復甦情景（V，U，W，L）：德國市場預測，2021年至2031年
  • 2021-2031年英國市場預測
    • 完善的研發基礎設施
    • 該地區精神疾病的患病率上升
    • 復甦情景（V，U，W，L）：英國市場預測，2021年至2031年
  • 2021-2031年法國市場預測
    • 對負擔得起的醫療服務的需求不斷增長
    • 對創新藥物和藥品的需求不斷增加
    • 復甦情景（V，U，W，L）：2021-2031年法國市場預測
  • 2021-2031年意大利市場預測
    • 製藥生產中心
    • 對用於治療精神障礙的先進療法的需求不斷增長
    • 復甦情景（V，U，W，L）：2021-2031年意大利市場預測
  • 2021-2031年西班牙市場預測
    • 強勁增長的西班牙經濟
    • 藥品需求受製藥行業增長的影響
    • 復甦情景（V，U，W，L）：2021-2031年西班牙市場預測
  • 2021-2031年俄羅斯市場預測
    • 未滿足的藥品需求
    • 政府對醫療基礎設施發展的支持
    • 復甦情景（V，U，W，L）：俄羅斯市場預測，2021年至2031年
  • 其他歐洲市場預測，2021年至2031年
    • 精神疾病的患病率上升
    • 復甦情景（V，U，W，L）：其他歐洲市場預測，2021年至2031年

第12章，2021-2031年亞太市場

  • 增長最快的亞太市場
  • 2021-2031年國家市場預測
  • 恢復方案（V，U，W，L）
  • 按藥品類別劃分的市場預測
  • 按指示的市場預測
  • 分銷渠道的市場預測
  • 2021-2031年日本市場預測
    • 日本在亞太地區獲得最大的市場份額
    • 政府倡議
    • 復甦情景（V，U，W，L）：日本市場預測，2021年至2031年
  • 2021-2031年中國市場預測
    • 大量老年人口的存在
    • 中國醫療費用增加
    • 復甦情景（V，U，W，L）：中國市場預測，2021年至2031年
  • 2021-2031年印度市場預測
    • 醫療基礎設施的發展
    • 精神疾病的患病率上升
    • 復甦情景（V，U，W，L）：印度市場預測，2021年至2031年
  • 2021-2031年澳大利亞市場預測
    • 政府計劃增加使用優質眼保健設施的機會
    • 建立醫療基礎設施
    • 復甦情景（V，U，W，L）：2021-2031年澳大利亞市場預測
  • 2021-2031年韓國市場預測
    • 提高人們的醫療保健意識
    • 抑鬱症患病率上升
    • 復甦情景（V，U，W，L）：韓國市場預測，2021年至2031年
  • 2021-2031年其他亞太市場預測
    • 可支配收入增加
    • 復甦情景（V，U，W，L）：2021-2031年其他亞太市場預測

第13章，2021-2031年的拉丁美洲市場

  • 拉丁美洲市場
  • 2021-2031年國家市場預測
  • 恢復方案（V，U，W，L）
  • 按藥品類別劃分的市場預測
  • 按指示的市場預測
  • 分銷渠道的市場預測
  • 2021-2031年巴西市場預測
    • 拉丁美洲增長最快的經濟體
    • 政府鼓勵維持本地生產的激勵措施
    • 復甦情景（V，U，W，L）：巴西市場預測，2021年至2031年
  • 墨西哥市場預測，2021年至2031年
    • 製造成本低於美國
    • 私營和公共部門的積極舉措
    • 復甦情景（V，U，W，L）：墨西哥市場預測，2021年至2031年
  • 2021-2031年阿根廷市場預測
    • 製藥業繁榮
    • 採用抑鬱症和其他精神科藥物
    • 復甦情景（V，U，W，L）：阿根廷市場預測，2021年至2031年
  • 2021-2031年其他拉丁美洲市場預測
    • 醫療基礎設施的發展
    • 復甦情景（V，U，W，L）：其他拉丁美洲市場預測，2021年至2031年

2021年至2031年第14章MEA市場

  • 精神疾病的患病率上升
  • 2021-2031年國家市場預測
  • 恢復方案（V，U，W，L）
  • 按藥品類別劃分的市場預測
  • 按指示的市場預測
  • 分銷渠道的市場預測
  • 2021-2031年南非市場預測
    • 該地區製藥和製藥公司的關注度日益提高
    • 支持性政府舉措
    • 復甦情景（V，U，W，L）：2021-2031年南非市場預測
  • 沙特阿拉伯市場預測，2021年至2031年
    • 存在巨大的增長機會
    • 存在巨大的增長機會
    • 復甦情景（V，U，W，L）：沙特阿拉伯市場預測，2021年至2031年
  • 2021-2031年其他MEA市場預測
    • 大型公司的強大實力
    • 精神疾病的患病率上升
    • 復甦情景（V，U，W，L）：2021年至2031年其他MEA市場預測

第15章公司簡介

  • 公司股份分析
  • 精神疾病藥物市場的最新趨勢，2017-2020年
  • Novartis AG
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • GlaxoSmithKline Pharmaceuticals Ltd.
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • Pfizer Inc.
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • 艾伯維（AbbVie Inc.）
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • Johnson & Johnson
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • AstraZeneca
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • Otsuka Pharmaceuticals
    • 公司快照
    • 公司簡介
    • 產品基準
    • 2017-2020年的最新趨勢
  • Eli Lilly and Company
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • H. Lundbeck A/S
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • Takeda Pharmaceutical Company Ltd.
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • Bausch Health
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
  • Mallinckrodt Pharmaceuticals
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
  • Teva Pharmaceutical Industries Ltd.
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢
  • Merck & Co., Inc.
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
  • Bristol-Myers Squibb
    • 公司快照
    • 公司簡介
    • 財務分析
    • 產品基準
    • 2017-2020年的最新趨勢

第16章結論和建議

  • 結論
  • 推薦
目錄
Product Code: PHA1072

Title:
Mental Disorder Drugs Market Report 2021-2031
Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios.

Mental Disorder Drugs Market - reveals latest trends, opportunities, predicted revenues, and competitive analysis. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.

Global mental disorder drugs market is projected to reach at a market value of US$xx billion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of mental disorders including depression, bipolar disorder, anxiety, and schizophrenia is a major factor that drives the demand for mental disorder drugs. Other key drivers boosting the market growth are growing mental health awareness in developing countries; adoption of mental disorder drugs for treatment & maintenance therapy; and rising R&D investment by the leading pharmaceutical companies in the area of mental health. In addition, the COVID-19 pandemic has a significant impact on the mental disorder drugs market. The COVID-19 pandemic has resulted in a growing incidence of mental disorders due to unemployment, financial crisis, health issues, and stress. Thus, the demand for mental disorder drugs is expected to rise during the forecast period.

Visiongain's report shows you the potential revenues streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the mental disorder drugs industry.

How this report will benefit you

Visiongain's new study is envisioned for anyone requiring commercial in-depth analyses for the global mental disorder drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for mental disorder drugs. Get the financial analysis of the overall market and different segments including by drug class, route of administration, usability, and distribution channel. High opportunity remains in this fast-growing mental disorder drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefit in the near future. Moreover, the report would help you to improve your strategic decision making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise productivity of the company.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
  • It also includes growth rates for different 5 regional markets along with 18 countries and COVID-19 impact analysis on each market
  • The profiles of the top 15 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
  • The COVID-19 has a positive impact on the mental disorder drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.

Discover sales forecasts for the global and regional market forecasts from 2021-2031

Along with revenue prediction for the overall global market, there is segmentation by region for 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA and 20 major countries.

Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class

  • SSRIs
  • SNRIs
  • Atypical Antipsychotics
  • TCAs
  • SARIs
  • Benzodiazepines
  • MAOIs
  • Others

Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication

  • Depression
  • Schizophrenia
  • Bipolar disorder
  • Post-traumatic Stress Disorder
  • Others

Global Mental Disorder Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional market revenue and growth forecasts from 2021 to 2031:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Detailed profiles of 15 leading companies that are operating in the market

The report includes profiles of 15 major companies involved in the mental disorder drugs market. The companies profiled in this report include: AbbVie, AstraZeneca, Bausch Health, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Merck, Novartis, Otsuka Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Teva Pharmaceutical Industries.

Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

In summary, our 429-page report delivers you with the following knowledge:

  • Revenue forecasts from 2021 to 2031 for the global mental disorder drugs market and subsegments (by drug class, indication, distribution channel, and region)- discover the industry's prospects, finding the most lucrative areas for investments and revenue generation
  • Detailed profiles of top 15 mental disorder drugs manufacturers, with financial overviews for net revenues, operating income, R&D investment, and segment revenues
  • Revenue forecasts from 2021 to 2031 for 5 regional markets - See forecasts for the mental disorder drugs market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Information found nowhere else

With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the mental disorder drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.

The Mental Disorder Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the mental disorder drugs industry.

Buy our report today “Mental Disorder Drugs Market Report 2021-2031: Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Mental Disorder Drugs Companies AND COVID-19 Recovery Scenarios”. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Mental Disorder Drugs Market
    • 1.1.1 What Is Mental Disorder?
    • 1.1.2 Types of Mental Disorders
    • 1.1.3 Prevalence and Mortality for Mental Disorders
  • 1.2 Why You Should Read This Report
  • 1.3 What This Report Delivers
  • 1.4 Key Questions Answered By This Analytical Report Include:
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
    • 1.6.3 Market Evaluation & Forecast Methodology
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2 Executive Summary

3 Market Dynamics

  • 3.1 Drivers
    • 3.1.1 Development of Advanced Mental Disorder Drugs
    • 3.1.2 Increasing Prevalence of Mental Disorders
    • 3.1.3 Escalating of Mental Healthcare Awareness
  • 3.2 Restraints
    • 3.2.1 Increasing Development of Novel Drugs
    • 3.2.2 Social Stigma of Mental Disorders
    • 3.2.3 Stringent Regulatory Guidelines for New Drug Approval
  • 3.3 Opportunities
    • 3.3.1 Growing Demand for Cutting-Edge Therapeutic Treatments for Mental Disorders to Aid Market Growth
    • 3.3.2 Increase in Geriatric Population
  • 3.4 Trends
    • 3.4.1 Mergers, Agreements, and Acquisitions by the Market Players
    • 3.4.2 Expected Launch of New Drugs is Expected to Drive the Market Growth
  • 3.5 SWOT Analysis
    • 3.5.1 Strengths: The Most Dynamic Area of the Mental Disorders Market
    • 3.5.2 Weaknesses
    • 3.5.3 Opportunities
      • 3.5.3.1 Increasing Mergers & Acquisitions and Collaborations
      • 3.5.3.2 Large Amount of R&D Investment
    • 3.5.4 Threats
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Supplier: Moderate
    • 3.6.2 Bargaining Power of Buyer: Moderate
    • 3.6.3 Competitive Rivalry: High
    • 3.6.4 Threat of New Entrants: Moderate
    • 3.6.5 Threat of Substitutes: Moderate
  • 3.7 PEST Analysis
    • 3.7.1 Political Factors Impacting Mental Disorder Drugs Market
    • 3.7.2 Economic Factors Impacting Mental Disorder Drugs Market
    • 3.7.3 Social Factors Impacting Mental Disorder Drugs Market
    • 3.7.4 Technological Factors Impacting Mental Disorder Drugs Market

4 Global Mental Disorder Drugs Market Forecast, 2021-2031

  • 4.1 Global Mental Disorder Drugs Market Forecast 2021-2031

5 COVID-19 Impact: Global Mental Disorder Drugs Market

  • 5.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
  • 5.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
  • 5.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
  • 5.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth

6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Drug Class

  • 6.1 Global SSRIs Segment: Revenue Forecast 2021-2031
    • 6.1.1 Largest Revenue Grossing Segment
    • 6.1.2 Recovery Forecasts (V, U, W, L)
  • 6.2 Global SNRIs Segment: Revenue Forecast 2021-2031
    • 6.2.1 Increase in Adoption of These Drugs for the Treatment of Mental Disorders
    • 6.2.2 Recovery Forecasts (V, U, W, L)
  • 6.3 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031
    • 6.3.1 Atypical Antipsychotics Segment is Expected to Grow at a Lucrative Growth Rate
    • 6.3.2 Recovery Forecasts (V, U, W, L)
  • 6.4 Global TCAs Segment: Revenue Forecast 2021-2031
    • 6.4.1 TCAs Play an In the Treatment of Severe Depression
    • 6.4.2 Recovery Forecasts (V, U, W, L)
  • 6.5 Global SARIs Segment: Revenue Forecast 2021-2031
    • 6.5.1 SARIs Are Mainly Used For The Treatment MDD
    • 6.5.2 Recovery Forecasts (V, U, W, L)
  • 6.6 Global Benzodiazepines Segment: Revenue Forecast 2021-2031
    • 6.6.1 Benzodiazepines Segment is Presumed to Witness Moderate Growth over the Forecast Period
    • 6.6.2 Recovery Forecasts (V, U, W, L)
  • 6.7 Global MAOIs Segment: Revenue Forecast 2021-2031
    • 6.7.1 MAOIs Segment Expected To Witness Lucrative CAGR during the Forecast Period
    • 6.7.2 Recovery Forecasts (V, U, W, L)
  • 6.8 Global Others Segment: Revenue Forecast 2021-2031
    • 6.8.1 Growing Demand for Advanced Drugs Is Expected to Propel the Segment Growth
    • 6.8.2 Recovery Forecasts (V, U, W, L)

7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 by Indication

  • 7.1 Global Depression Segment: Revenue Forecast 2021-2031
    • 7.1.1 Largest Revenue Grossing Segment
    • 7.1.2 Recovery Forecasts (V, U, W, L)
  • 7.2 Global Schizophrenia Segment: Revenue Forecast 2021-2031
    • 7.2.1 Mounting Prevalence of Schizophrenia Worldwide Will Drive the Segment Growth
    • 7.2.2 Recovery Forecasts (V, U, W, L)
  • 7.3 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031
    • 7.3.1 Adoption of Generic Drugs for the Treatment of Bipolar Disorder
    • 7.3.2 Recovery Forecasts (V, U, W, L)
  • 7.4 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031
    • 7.4.1 Growing R&D expenditure in the development of therapeutically advanced mental disorder drugs
    • 7.4.2 Recovery Forecasts (V, U, W, L)
  • 7.5 Global Others Segment: Revenue Forecast 2021-2031
    • 7.5.1 Rising Prevalence of Other Mental Disorders
    • 7.5.2 Recovery Forecasts (V, U, W, L)

8 Mental Disorder Drugs Market by Distribution Channel Forecast, 2021-2031

  • 8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
    • 8.1.1 Largest Revenue Generating Segment
    • 8.1.2 Recovery Scenarios (V, U, W, L)
  • 8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
    • 8.2.1 Fastest Growing Segment in the Market
    • 8.2.2 Recovery Scenarios (V, U, W, L)
  • 8.3 Others Segment Market Forecast, 2021-2031
    • 8.3.1 Developing Healthcare Infrastructure Is Expected To Drive the Market Growth
    • 8.3.2 Recovery Scenarios (V, U, W, L)

9 Global Mental Disorder Drugs Market Forecast, 2021-2031

  • 9.1 Global Mental Disorder Drugs Market by Region Forecast 2021-2031
  • 9.2 Recovery Scenarios (V, U, W, L)

10 North America Mental Disorder Drugs Market, 2021-2031

  • 10.1 North America is The Largest Revenue Grossing Region in the Global Market
  • 10.2 North America Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 10.3 Recovery Scenarios (V, U, W, L)
  • 10.4 North America Mental Disorder Drugs Market Forecast by Drug Class
  • 10.5 North America Mental Disorder Drugs Market Forecast by Indication
  • 10.6 North America Mental Disorder Drugs Market Forecast by Distribution Channel
  • 10.7 U.S. Mental Disorder Drugs Market Forecast, 2021-2031
    • 10.7.1 Rise in the Number of Drug Approvals
    • 10.7.2 Presence of Highly Developed Healthcare Infrastructure
    • 10.7.3 Recovery Scenarios (V, U, W, L): U.S. Mental Disorder Drugs Market Forecast, 2021-2031
  • 10.8 Canada Mental Disorder Drugs Market Forecast, 2021-2031
    • 10.8.1 Anticipated To Witness the Fastest Growth in the North America Region
    • 10.8.2 Benefits of Manufacturing and R&D Operations in Canada
    • 10.8.3 Recovery Scenarios (V, U, W, L): Canada Mental Disorder Drugs Market Forecast, 2021-2031

11 Europe Mental Disorder Drugs Market, 2021-2031

  • 11.1 Second Largest Market in the Global Market
  • 11.2 Europe Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 11.3 Recovery Scenarios (V, U, W, L)
  • 11.4 Europe Mental Disorder Drugs Market Forecast by Drug Class
  • 11.5 Europe Mental Disorder Drugs Market Forecast by Indication
  • 11.6 Europe Mental Disorder Drugs Market Forecast by Distribution Channel
  • 11.7 Germany Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.7.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
    • 11.7.2 One of the Oldest Universal Health Systems within Europe
    • 11.7.3 Recovery Scenarios (V, U, W, L): Germany Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.8 UK Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.8.1 Presence of Well-Developed R&D Infrastructure
    • 11.8.2 Increasing Prevalence of Mental Disorders in This Region
    • 11.8.3 Recovery Scenarios (V, U, W, L): UK Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.9 France Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.9.1 Growing Demand For Affordable Healthcare Services
    • 11.9.2 Growing Demand for Innovative Medicine and Pharmaceutical
    • 11.9.3 Recovery Scenarios (V, U, W, L): France Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.10 Italy Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.10.1 Pharmaceutical Manufacturing Hub
    • 11.10.2 Growing Demand for Advanced Therapies for the Treatment of Mental Disorders
    • 11.10.3 Recovery Scenarios (V, U, W, L): Italy Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.11 Spain Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.11.1 Spanish Economy Is Growing Strong
    • 11.11.2 Demand for Drugs Is Influenced By the Growth of the Pharmaceutical Industry
    • 11.11.3 Recovery Scenarios (V, U, W, L): Spain Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.12 Russia Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.12.1 Unmet Pharmaceutical Needs
    • 11.12.2 Government Support For Development of the Healthcare Infrastructure
    • 11.12.3 Recovery Scenarios (V, U, W, L): Russia Mental Disorder Drugs Market Forecast, 2021-2031
  • 11.13 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031
    • 11.13.1 Increasing Prevalence of Mental Disorders
    • 11.13.2 Recovery Scenarios (V, U, W, L): Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031

12 Asia Pacific Mental Disorder Drugs Market, 2021-2031

  • 12.1 Asia Pacific is the Fastest Growing Market
  • 12.2 Asia Pacific Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 12.3 Recovery Scenarios (V, U, W, L)
  • 12.4 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class
  • 12.5 Asia Pacific Mental Disorder Drugs Market Forecast by Indication
  • 12.6 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel
  • 12.7 Japan Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.7.1 Japan Accounted For the Largest Market Share in the Asia Pacific Region
    • 12.7.2 Government Initiatives
    • 12.7.3 Recovery Scenarios (V, U, W, L): Japan Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.8 China Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.8.1 Presence of Large Geriatric Population
    • 12.8.2 Increasing Healthcare Spending In China
    • 12.8.3 Recovery Scenarios (V, U, W, L): China Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.9 India Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.9.1 Developing Healthcare Infrastructure
    • 12.9.2 Increasing Prevalence of Mental Disorders
    • 12.9.3 Recovery Scenarios (V, U, W, L): India Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.10 Australia Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.10.1 Government Programs to Expand Access to Quality Eye Care Facilities
    • 12.10.2 Well Established Healthcare Infrastructure
    • 12.10.3 Recovery Scenarios (V, U, W, L): Australia Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.11 South Korea Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.11.1 Growing Healthcare Awareness among People
    • 12.11.2 Increasing Prevalence of Depression
    • 12.11.3 Recovery Scenarios (V, U, W, L): South Korea Mental Disorder Drugs Market Forecast, 2021-2031
  • 12.12 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031
    • 12.12.1 Rising Disposable Income
    • 12.12.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031

13 Latin America Mental Disorder Drugs Market, 2021-2031

  • 13.1 Latin America Mental Disorder Drugs Market
  • 13.2 Latin America Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 13.3 Recovery Scenarios (V, U, W, L)
  • 13.4 Latin America Mental Disorder Drugs Market Forecast by Drug Class
  • 13.5 Latin America Mental Disorder Drugs Market Forecast by Indication
  • 13.6 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel
  • 13.7 Brazil Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.7.1 Fastest Growing Economies in Latin America
    • 13.7.2 Government Incentives to Keep Manufacturing Local
    • 13.7.3 Recovery Scenarios (V, U, W, L): Brazil Mental Disorder Drugs Market Forecast, 2021-2031
  • 13.8 Mexico Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.8.1 Lower Manufacturing Costs than In the US
    • 13.8.2 Favourable Initiatives Undertaken By Private and Public Sectors
    • 13.8.3 Recovery Scenarios (V, U, W, L): Mexico Mental Disorder Drugs Market Forecast, 2021-2031
  • 13.9 Argentina Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.9.1 Boom in Pharmaceutical Industry
    • 13.9.2 Adoption of Depression and Other Mental Disorders Drugs
    • 13.9.3 Recovery Scenarios (V, U, W, L): Argentina Mental Disorder Drugs Market Forecast, 2021-2031
  • 13.10 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031
    • 13.10.1 Developing Healthcare Infrastructure
    • 13.10.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031

14 MEA Mental Disorder Drugs Market, 2021-2031

  • 14.1 Rising Prevalence of Mental Disorders
  • 14.2 MEA Mental Disorder Drugs Market by Country, Forecast 2021-2031
  • 14.3 Recovery Scenarios (V, U, W, L)
  • 14.4 MEA Mental Disorder Drugs Market Forecast by Drug Class
  • 14.5 MEA Mental Disorder Drugs Market Forecast by Indication
  • 14.6 MEA Mental Disorder Drugs Market Forecast by Distribution Channel
  • 14.7 South Africa Mental Disorder Drugs Market Forecast, 2021-2031
    • 14.7.1 Increasing Focus of Pharmaceutical & Pharmaceutical Companies in This Region
    • 14.7.2 Supportive Government Initiatives
    • 14.7.3 Recovery Scenarios (V, U, W, L): South Africa Mental Disorder Drugs Market Forecast, 2021-2031
  • 14.8 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
    • 14.8.1 Presence of Huge Growth Opportunities
    • 14.8.2 Presence of Huge Growth Opportunities
    • 14.8.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031
  • 14.9 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031
    • 14.9.1 Strong Presence Of Leading Companies
    • 14.9.2 Growing Prevalence of Mental Disorders
    • 14.9.3 Recovery Scenarios (V, U, W, L): Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031

15 Company Profiles

  • 15.1 Company Share Analysis
  • 15.2 Mental Disorder Drugs Market Recent Developments, 2017-2020
  • 15.3 Novartis AG
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2015-2019
      • 15.3.3.2 Product Revenue Shares, 2019
      • 15.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
      • 15.3.3.4 Regional Revenue Shares, 2019
    • 15.3.4 Product Benchmarking
    • 15.3.5 Recent Developments, 2017-2020
  • 15.4 GlaxoSmithKline Pharmaceuticals Ltd.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2015-2019
      • 15.4.3.2 Product Revenue Shares, 2019
      • 15.4.3.3 Pharmaceuticals Segment Revenue Shares, 2019
      • 15.4.3.4 Regional Revenue Shares, 2019
    • 15.4.4 Product Benchmarking
    • 15.4.5 Recent Developments, 2017-2020
  • 15.5 Pfizer Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2015-2019
      • 15.5.3.2 Product Revenue Shares, 2019
      • 15.5.3.3 Regional Revenue Shares, 2019
    • 15.5.4 Product Benchmarking
    • 15.5.5 Recent Developments, 2017-2020
  • 15.6 AbbVie Inc.
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2015-2019
      • 15.6.3.2 Product Revenue Shares, 2019
      • 15.6.3.3 Regional Revenue Shares, 2019
    • 15.6.4 Product Benchmarking
    • 15.6.5 Recent Developments, 2017-2020
  • 15.7 Johnson & Johnson
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2015-2019
      • 15.7.3.2 Product Revenue Shares, 2019
      • 15.7.3.3 Regional Revenue Shares, 2019
    • 15.7.4 Product Benchmarking
    • 15.7.5 Recent Developments, 2017-2020
  • 15.8 AstraZeneca
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2015-2019
      • 15.8.3.2 Product Revenue Shares, 2019
      • 15.8.3.3 Regional Revenue Shares, 2019
    • 15.8.4 Product Benchmarking
    • 15.8.5 Recent Developments, 2017-2020
  • 15.9 Otsuka Pharmaceuticals
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Recent Developments, 2017-2020
  • 15.10 Eli Lilly and Company
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2015-2019
      • 15.10.3.2 Product Revenue Shares, 2019
      • 15.10.3.3 Regional Revenue Shares, 2019
    • 15.10.4 Product Benchmarking
    • 15.10.5 Recent Developments, 2017-2020
  • 15.11 H. Lundbeck A/S
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2015-2019
      • 15.11.3.2 Regional Revenue Shares, 2019
    • 15.11.4 Product Benchmarking
    • 15.11.5 Recent Developments, 2017-2020
  • 15.12 Takeda Pharmaceutical Company Ltd.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2015-2019
      • 15.12.3.2 Regional Revenue Shares, 2019
    • 15.12.4 Product Benchmarking
    • 15.12.5 Recent Developments, 2017-2020
  • 15.13 Bausch Health
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2015-2019
      • 15.13.3.2 Product Revenue Shares, 2019
      • 15.13.3.3 Regional Revenue Shares, 2019
    • 15.13.4 Product Benchmarking
  • 15.14 Mallinckrodt Pharmaceuticals
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2015-2019
      • 15.14.3.2 Product Revenue Shares, 2019
      • 15.14.3.3 Regional Revenue Shares, 2019
    • 15.14.4 Product Benchmarking
  • 15.15 Teva Pharmaceutical Industries Ltd.
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2015-2019
      • 15.15.3.2 Product Revenue Shares, 2019
      • 15.15.3.3 Regional Revenue Shares, 2019
    • 15.15.4 Product Benchmarking
    • 15.15.5 Recent Developments, 2017-2020
  • 15.16 Merck & Co., Inc.
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Financial Analysis
      • 15.16.3.1 Net Revenue, 2015-2019
      • 15.16.3.2 Product Revenue Shares, 2019
      • 15.16.3.3 Regional Revenue Shares, 2019
    • 15.16.4 Product Benchmarking
  • 15.17 Bristol-Myers Squibb
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Financial Analysis
      • 15.17.3.1 Net Revenue, 2015-2019
      • 15.17.3.2 Regional Revenue Shares, 2019
    • 15.17.4 Product Benchmarking
    • 15.17.5 Recent Developments, 2017-2020

16 Conclusion and Recommendations

  • 16.1 Conclusion
  • 16.2 Recommendations

List of Tables

  • Table 1 Mental Disorder Types
  • Table 2 Global Mental Disorder Drugs Market, 2021 & 2031 (US$ bn, CAGR %)
  • Table 3 Worldwide Mental Disorders Prevalence, 2017
  • Table 4 Major M&A and Collaborations: Mental Disorder Drugs Market
  • Table 5 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
  • Table 6 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
  • Table 7 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
  • Table 8 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
  • Table 9 Global Mental Disorder Drugs Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
  • Table 10 Global Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 11 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 12 "V" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 13 "U" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 14 "W" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 15 "L" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 16 Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 17 "V" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 18 "U" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 19 "W" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 20 "L" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 21 Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 22 "V" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 23 "U" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 24 "W" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 25 "L" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 26 Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 27 "V" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 28 "U" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 29 "W" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 30 "L" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 31 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 32 "V" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 33 "U" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 34 "W" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 35 "L" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 36 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 37 "V" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 38 "U" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 39 "W" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 40 "L" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 41 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 42 "V" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 43 "U" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 44 "W" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 45 "L" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 46 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 47 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 48 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 49 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 50 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 51 Global Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 53 "V" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 54 "U" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 55 "W" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 56 "L" Shaped Recovery: Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 58 "V" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 59 "U" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 60 "W" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 61 "L" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 63 "V" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 64 "U" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 65 "W" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 66 "L" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 68 "V" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 69 "U" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 70 "W" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 71 "L" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 73 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 74 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 75 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 76 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 77 Global Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 88 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 89 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 90 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 91 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 92 Global Mental Disorder Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 93 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 94 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 95 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 96 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 97 Global Mental Disorder Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 98 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 99 North America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 100 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 101 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 102 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 103 North America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 104 North America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 105 North America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 117 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 118 Europe Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 119 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 120 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 121 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 122 Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 123 Europe Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 124 Europe Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR %)
  • Table 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 161 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 163 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 164 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 165 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 166 Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 167 Asia Pacific Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 168 Asia Pacific Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 200 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 201 Latin America Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 202 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 203 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 1 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 204 Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 205 Latin America Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 206 Latin America Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 207 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 208 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 213 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 218 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 223 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 2 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 228 MEA Mental Disorder Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 229 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 230 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 231 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 232 MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 233 MEA Mental Disorder Drugs Market Size Forecast by Drug Class, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 234 MEA Mental Disorder Drugs Market Share Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 235 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 236 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 237 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 241 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 242 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 246 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 247 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 251 Mental Disorder Drugs Market Recent Developments, 2017-2020
  • Table 252 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 253 Novatis AG: Product Benchmarking
  • Table 254 Novatis AG: Recent Developments, 2017-2020
  • Table 255 GlaxoSmithKline Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 256 GlaxoSmithKline Pharmaceuticals Ltd.: Product Benchmarking
  • Table 257 GlaxoSmithKline Pharmaceuticals Ltd.: Recent Developments, 2017-2020
  • Table 258 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 259 Pfizer Inc.: Product Benchmarking
  • Table 260 Pfizer Inc.: Recent Developments, 2017-2020
  • Table 261 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 262 AbbVie Inc.: Product Benchmarking
  • Table 263 AbbVie Inc.: Recent Developments, 2017-2020
  • Table 264 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 265 Johnson & Johnson: Product Benchmarking
  • Table 266 Johnson & Johnson: Recent Developments, 2017-2020
  • Table 267 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 268 AstraZeneca: Product Benchmarking
  • Table 269 AstraZeneca: Recent Developments, 2017-2020
  • Table 270 Otsuka Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 271 Otsuka Pharmaceuticals: Product Benchmarking
  • Table 272 Otsuka Pharmaceuticals: Recent Developments, 2017-2020
  • Table 273 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 274 Eli Lilly and Company: Product Benchmarking
  • Table 275 Eli Lilly and Company: Recent Developments, 2017-2020
  • Table 276 H. Lundbeck A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 277 H. Lundbeck A/S: Product Benchmarking
  • Table 278 H. Lundbeck A/S: Recent Developments, 2017-2020
  • Table 279 Takeda Pharmaceutical Company Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 280 Takeda Pharmaceutical Company Ltd.: Product Benchmarking
  • Table 281 Takeda Pharmaceutical Company Ltd.: Recent Developments, 2017-2020
  • Table 282 Bausch Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 283 Bausch Health: Product Benchmarking
  • Table 284 Mallinckrodt Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 285 Mallinckrodt Pharmaceuticals: Product Benchmarking
  • Table 286 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 287 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 288 Teva Pharmaceutical Industries Ltd.: Recent Developments, 2017-2020
  • Table 289 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 290 Merck & Co., Inc.: Product Benchmarking
  • Table 291 Bristol-Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 292 Bristol-Myers Squibb: Product Benchmarking
  • Table 293 Bristol-Myers Squibb: Recent Developments, 2017-2020

List of Figures

  • Figure 1 Global Mental Disorder Drugs Market Segmentation
  • Figure 2 Global Mental Disorder Drugs Market: Market Trends
  • Figure 3 Global Mental Disorder Drugs Market: SWOT Analysis
  • Figure 4 Global Mental Disorder Drugs Market: Porter's Five Forces Analysis
  • Figure 5 Global Mental Disorder Drugs Market: PEST Analysis
  • Figure 6 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %)
  • Figure 7 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "V" Shaped Recovery
  • Figure 8 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "U" Shaped Recovery
  • Figure 9 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "W" Shaped Recovery
  • Figure 10 Global Mental Disorder Drugs Market Size Forecast 2021-2031 (US$bn, AGR %): "L" Shaped Recovery
  • Figure 11 Global Mental Disorder Drugs Market Share Forecast by Drug Class, 2021, 2026, 2031 (%)
  • Figure 12 Global SSRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 13 "V" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 14 "U" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 15 "W" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 16 "L" Shaped Recovery: Global SSRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 17 Global SNRIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 18 "V" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 19 "U" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 20 "W" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 21 "L" Shaped Recovery: Global SNRIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 22 Global Atypical Antipsychotics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 23 "V" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 24 "U" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 25 "W" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 26 "L" Shaped Recovery: Global Atypical Antipsychotics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 27 Global TCAs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 28 "V" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 29 "U" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 30 "W" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 31 "L" Shaped Recovery: Global TCAs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 32 Global SARIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 33 "V" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 34 "U" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 35 "W" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 36 "L" Shaped Recovery: Global SARIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 37 Global Benzodiazepines Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 38 "V" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 39 "U" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 40 "W" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 41 "L" Shaped Recovery: Global Benzodiazepines Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 42 Global MAOIs Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 43 "V" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 44 "U" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 45 "W" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 46 "L" Shaped Recovery: Global MAOIs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 47 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 48 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 49 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 50 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 51 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 52 Global Depression Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 53 "V" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 54 "U" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 55 "W" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 56 "L" Shaped Recovery: Global Depression Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 57 Global Schizophrenia Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 58 "V" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 59 "U" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 60 "W" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 61 "L" Shaped Recovery: Global Schizophrenia Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 62 Global Bipolar Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 63 "V" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 64 "U" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 65 "W" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 66 "L" Shaped Recovery: Global Bipolar Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 67 Global Post-traumatic Stress Disorder Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 68 "V" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 69 "U" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 70 "W" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 71 "L" Shaped Recovery: Global Post-traumatic Stress Disorder Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 72 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 73 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 74 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 75 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 76 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 77 Global Mental Disorder Drugs Market Share Forecast by Distribution Channel, 2021, 2026, 2031 (%)
  • Figure 78 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 79 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 80 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 81 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 82 Global Mental Disorder Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 83 Global Mental Disorder Drugs Market for Retail Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 84 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 85 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 86 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 87 Global Mental Disorder Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 88 Global Mental Disorder Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 89 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 90 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 91 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 92 Global Mental Disorder Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 93 Global Mental Disorder Drugs Market Share Forecast by Region 2021, 2026, 2031 (%)
  • Figure 94 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): "V" Shaped Recovery
  • Figure 95 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion): "U" Shaped Recovery
  • Figure 96 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 97 Global Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 98 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 99 North America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 100 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 101 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 102 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 103 North America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 104 North America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 105 North America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 106 North America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 107 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 108 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 109 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 110 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 111 U.S. Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 112 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 113 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 114 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 115 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 116 Canada Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 117 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 118 Europe Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 119 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 120 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 121 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 122 Europe Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 123 Europe Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 124 Europe Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 125 Europe Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 126 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 127 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 128 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 129 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 130 Germany Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 131 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 132 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 133 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 134 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 135 UK Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 136 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 137 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 138 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 139 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 140 France Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 141 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 142 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 143 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 144 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 145 Italy Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 146 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 147 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 148 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 149 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 150 Spain Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 151 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 152 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 153 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 154 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 155 Russia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 156 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 157 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 158 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 159 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 160 Rest of Europe Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 161 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 162 Asia Pacific Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 163 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 164 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 165 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 166 Asia Pacific Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 167 Asia Pacific Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 168 Asia Pacific Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 169 Asia Pacific Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 170 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 171 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 172 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 173 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 174 Japan Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 175 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 176 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 177 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 178 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 179 China Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 180 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 181 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 182 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 183 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 184 India Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 185 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 186 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 187 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 188 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 189 Australia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 190 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 191 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 192 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 193 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 194 South Korea Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 195 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 196 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 197 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 198 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 199 Rest of Asia Pacific Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 200 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 201 Latin America Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 202 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 203 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 204 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 205 Latin America Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 206 Latin America Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 207 Latin America Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 208 Latin America Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 209 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 210 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 211 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 212 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 213 Brazil Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 214 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 215 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 216 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 217 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 218 Mexico Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 219 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 220 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 221 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 222 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 223 Argentina Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 224 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 225 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 226 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 227 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 228 Rest of Latin America Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 229 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 230 MEA Mental Disorder Drugs Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 231 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 232 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 233 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 234 MEA Mental Disorder Drugs Market Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 235 MEA Mental Disorder Drugs Market Forecast by Drug Class, 2021-2031 (US$ billion)
  • Figure 236 MEA Mental Disorder Drugs Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 237 MEA Mental Disorder Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion)
  • Figure 238 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 239 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 240 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 241 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 242 South Africa Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 243 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 244 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 245 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 246 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 247 Saudi Arabia Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 248 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 249 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 250 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 251 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 252 Rest of MEA Mental Disorder Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 253 Global Mental Disorder Drugs Market: Company Share Analysis, 2020
  • Figure 254 Novatis AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 255 Novatis AG: Product Revenue Shares, 2019
  • Figure 256 Novartis AG.: Pharmaceuticals Business Unit Revenue Shares, 2019
  • Figure 257 Novatis AG: Regional Revenue Shares, 2019
  • Figure 258 GlaxoSmithKline Pharmaceuticals Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 259 GlaxoSmithKline Pharmaceuticals Ltd.: Product Revenue Shares, 2019
  • Figure 260 GlaxoSmithKline Pharmaceuticals Ltd.: Pharmaceutical Segment Revenue Shares, 2019
  • Figure 261 GlaxoSmithKline Pharmaceuticals Ltd.: Regional Revenue Shares, 2019
  • Figure 262 Pfizer Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 263 Pfizer Inc.: Product Revenue Shares, 2019
  • Figure 264 Pfizer Inc.: Regional Revenue Shares, 2019
  • Figure 265 AbbVie Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 266 AbbVie Inc.: Product Revenue Shares, 2019
  • Figure 267 AbbVie Inc.: Regional Revenue Shares, 2019
  • Figure 268 Johnson & Johnson: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 269 Johnson & Johnson: Pharmaceutical Segment Revenue Shares, 2019
  • Figure 270 Johnson & Johnson: Business Segment Revenue Shares, 2019
  • Figure 271 AstraZeneca: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 272 AstraZeneca: Product Revenue Shares, 2019
  • Figure 273 AstraZeneca: Regional Revenue Shares, 2019
  • Figure 274 Eli Lilly and Company: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 275 Eli Lilly and Company: Product Revenue Shares, 2019
  • Figure 276 Eli Lilly and Company: Regional Revenue Shares, 2019
  • Figure 277 H. Lundbeck A/S: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 278 H. Lundbeck A/S: Regional Revenue Shares, 2019
  • Figure 279 Takeda Pharmaceutical Company Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 280 Takeda Pharmaceutical Company Ltd.: Regional Revenue Shares, 2019
  • Figure 281 Bausch Health: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 282 Bausch Health: Product Revenue Shares, 2019
  • Figure 283 Bausch Health: Regional Revenue Shares, 2019
  • Figure 284 Mallinckrodt Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 285 Mallinckrodt Pharmaceuticals: Product Revenue Shares, 2019
  • Figure 286 Mallinckrodt Pharmaceuticals: Regional Revenue Shares, 2019
  • Figure 287 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 288 Teva Pharmaceutical Industries Ltd.: Product Revenue Shares, 2019
  • Figure 289 Teva Pharmaceutical Industries Ltd.: Regional Revenue Shares, 2019
  • Figure 290 Merck & Co., Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 291 Merck & Co., Inc.: Product Revenue Shares, 2019
  • Figure 292 Merck & Co., Inc.: Regional Revenue Shares, 2019
  • Figure 293 Bristol-Myers Squibb: Net Revenue, 2015-2019 (US$ billion, AGR%)
  • Figure 294 Bristol-Myers Squibb: Regional Revenue Shares, 2019

Companies Profiled in the Report

  • AbbVie Inc.
  • AstraZeneca
  • Bausch Health
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • H. Lundbeck A/S
  • Johnson and Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • List of Companies Mentioned in the Report
  • AbbVie Inc.
  • Actelion Ltd
  • Allergan plc
  • AstraZeneca
  • Aurobindo Pharma
  • Bausch Health
  • Bristol Myers Squibb Company
  • Cadent Therapeutics
  • Celgene Corporation
  • Concordia Pharms Inc
  • Dr. Reddy's Labs
  • Eli Lilly and Company
  • Gedeon Richter Plc.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • H. Lundbeck A/S
  • Hoffmann-La Roche
  • Janssen Holding GmbH
  • Janssen Pharmaceutical
  • Janssen Research & Development, LLC
  • Jazz Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Orchard Therapeutics
  • Osmotica Pharmaceutical Corp.
  • Otsuka Pharmaceutical Co., Ltd.
  • Par Pharmaceutical
  • Pear Therapeutics, Inc.,
  • Pfizer Inc.
  • Proteus Digital Health (Proteus)
  • Sandoz
  • Sanofi SA (France)
  • Sebela International Ltd.
  • Somerset Pharmaceuticals, Inc.
  • Strateos, Inc.
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd
  • Teva Canada Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals

List of Organizations Mentioned in the Report

  • Australian Government
  • Australian Institute of Health and Welfare
  • CAMH (Centre for Addiction and Mental Health)
  • Centers for Disease Control and Prevention (CDC)
  • Child Mind Institute
  • China's Ministry of Finance
  • Chinese government
  • European Union
  • EXIM bank
  • FDA Centre's for Drug Evaluation and Research
  • French Government
  • Government of Japan
  • Health Ministry (Italy)
  • Institute for Healthcare Improvement (IHI)
  • Italian Industry Group Farmindustria
  • Japanese Ministry of Health, Labour and Welfare
  • King Salman Humanitarian Aids & Relief Center
  • MHFA England
  • National Development and Reform Commission (NDRC)
  • National Institute of Health (NIH)
  • National Mental Health Institute
  • NCBI
  • NHS England
  • NHS England 's House of Care
  • Organisation for Economic Co-operation and Development (OECD)
  • Saudi Export Development Authority
  • US government
  • WHO
  • World Bank
  • World Economic Forum (WEF)